Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

This publication has 33 references indexed in Scilit:

• The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1
  Diabetologia, 2005
• Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region
  American Journal of Physiology-Endocrinology and Metabolism, 2004
• Incretins, insulin secretion and Type 2 diabetes mellitus
  Diabetologia, 2004
• Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells
  Autonomic Neuroscience, 2004
• The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
  Diabetes, 2003
• A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells
  The FASEB Journal, 2002
• Glucagon-like peptide containing pathways in the regulation of feeding behaviour
  International Journal of Obesity, 2001
• The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-l, but not to glucose-dependent insulinotropic polypeptide, in the portal vein
  Published by Elsevier ,1999
• Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients
  Diabetes Care, 1996
• Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum
  European Journal of Biochemistry, 1993